ArticleNarra J2026
Comparative study of quality of life between endometriosis patients receiving GnRH agonist and dienogest therapy: A cross-sectional study using Endometriosis Health Profile-30 (EHP-30).
Article in Narra J, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is a chronic gynecological disease that substantially impairs quality of life. Gonadotropin-releasing hormone (GnRH) agonists and dienogest are commonly used hormonal therapies for endometriosis; however, direct comparisons of their effects on quality of life remain limited. This study aimed to compare quality of life between patients with endometriosis receiving GnRH agonist and dienogest therapy using the Endometriosis Health Profile-30 (EHP-30). A comparative cross-sectional study was conducted among 100 patients with endometriosis at Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia, comprising 50 patients receiving GnRH agonist therapy and 50 receiving dienogest therapy. Quality of life was assessed using the Indonesian version of the EHP-30, with higher scores indicating poorer quality of life. Between-group comparisons and multiple linear regression were performed. Patients receiving dienogest had significantly lower total EHP-30 scores than those receiving GnRH agonist therapy (20.1±9.6 vs 43.7±14.9;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.